← Eichor
Study identifier: NCT06698796 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Condition: Dermatomyositis · Polymyositis  ·  Sponsor: Pfizer

PhasePhase 3
Planned participants211
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \[DM\] or polymyositis \[PM\]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM. DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hips, thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathies may find it difficult to climb stairs, get up from a seated position, or lift items above their head. People with DM can also have a skin rash. These disorders negatively impact the quality of life and functioning of patients. In addition to the above, these disorders can affect how the lungs and heart work. This study is seeking participants who took part in a DM and PM study with dazukibart before. Some participants will receive study medicine, and some participants will not receive study medicine and only complete safety follow-up. The study medicine will be given as an intravenous (IV) infusion (directly into the veins). This takes about 1 hour, every 4 weeks, from Day 1 to Week 48 (about 12 months) of the study. This will be followed by a safety follow-up period that lasts about 4 months after the last infusion. Participants who receive study medicine will have about 18 study visits …

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (24)

AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - GlendaleGlendale, Arizona, United StatesRecruiting
Arthritis & Rheumatology Research Institute, PLLCAllen, Texas, United StatesNot Yet Recruiting
Nerve & Muscle Center of TexasHouston, Texas, United StatesRecruiting
Rheumatology & Pulmonary ClinicBeckley, West Virginia, United StatesRecruiting
Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, Tucumán Province, ArgentinaRecruiting
Medical Center ArtmedPlovdiv, BulgariaRecruiting
Anhui Provincial HospitalHefei, Anhui, ChinaRecruiting
The Second Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi, ChinaRecruiting
The Second Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi, ChinaRecruiting
Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting
Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting
First Affiliated Hospital of Kunming Medical UniversityKunming, Yunnan, ChinaRecruiting

+ 12 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06698796